Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03707795 · ClinicalTrials.gov registry record · Early Phase 1
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study
A Early Phase 1 study, sponsored by Edward Kasaraskis.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03707795 is a Early Phase 1 study that has completed, run by Edward Kasaraskis. The registered enrollment target is 6 participants.
The verdict
NCT03707795, a Early Phase 1 study, has completed, sponsored by Edward Kasaraskis.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: * Attend all scheduled visits * Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study * Be completely honest with their answers to all questions * Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements.
Interventions
- DRUG Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2019-01-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03707795
The ClinicalTrials.gov registry entry for NCT03707795 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edward Kasaraskis, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days is the first listed.
NCT03707795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03707795 about?
NCT03707795 is a clinical study titled "Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study". By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body t...
What is the current status of trial NCT03707795?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2017-08-21. Estimated completion is 2019-01-10.
What interventions are being tested in trial NCT03707795?
The interventions under investigation include: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days (DRUG).
Who is sponsoring clinical trial NCT03707795?
This trial is sponsored by Edward Kasaraskis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.